Clinical trial NCT00003896 (phase 2, status: completed)
Conditions: fallopian tube cancer, ovarian cancer, peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: cisplatin, liposomal doxorubicin, paclitaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage III ovarian epithelial, fallopian tube, or primary
             peritoneal carcinoma

               -  Tumor involves one or both ovaries with microscopically confirmed peritoneal
                  metastasis outside the pelvis and/or regional lymph node metastasis

               -  No tumors of borderline or low malignant potential only

               -  Mixed Mullerian tumors allowed

          -  Must have optimal disease defined as no residual lesions after resection or residual
             disease such that no single lesion measures greater than 1 cm in diameter

          -  Must have undergone staging exploratory laparotomy with tumor debulking within the
             past 70 days

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Performance status:

          -  SWOG 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic:

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  SGOT or SGPT ≤ 2 times ULN

        Renal:

          -  Creatinine clearance ≥ 50 mL/min

        Cardiovascular:

          -  No congestive heart failure

          -  No cardiac arrhythmia

          -  No myocardial infarction or unstable angina within the past 6 months

          -  Patients with a history of myocardial disease must not have ischemia or pathologic
             arrhythmias and must have an ejection fraction > 50% by MUGA

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No active or uncontrolled infection

          -  No concurrent fever

          -  No grade 2 or greater sensory neuropathy

          -  No severe gastrointestinal symptoms (i.e., partial obstruction) and/or bleeding,
             diarrhea, or abdominal tenderness suggestive of peritoneal irritation or infection

          -  No erythema or tenderness of abdominal incision or port site suggestive of underlying
             infection

          -  No other malignancy within the past five years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for ovarian cancer

        Chemotherapy:

          -  No prior chemotherapy for ovarian cancer

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior pelvic radiotherapy for ovarian cancer

        Surgery:

          -  See Disease Characteristics

          -  Recovered from all reversible surgery-related toxic effects

        Other:

          -  No other concurrent antitumor treatment

          -  No concurrent antibiotics for infection of undetermined etiology